INAB

Company Overview — What Does IN8BIO, INC. Do?

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. IN8BIO, INC. (INAB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO William T. Ho and employs approximately 20 people. With a market capitalization of $14M, INAB is one of the notable companies in the Healthcare sector.

IN8BIO, INC. (INAB) Stock Rating — Avoid (April 2026)

As of April 2026, IN8BIO, INC. receives a Avoid rating with a composite score of 22.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.INAB ranks #4,206 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IN8BIO, INC. ranks #751 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INAB Stock Price and 52-Week Range

IN8BIO, INC. (INAB) currently trades at $1.40. The stock lost $0.03 (2.1%) in the most recent trading session. The 52-week high for INAB is $4.17, which means the stock is currently trading -66.4% from its annual peak. The 52-week low is $0.10, putting the stock 1286.1% above its annual trough. Recent trading volume was 35K shares, suggesting relatively thin trading activity.

Is INAB Overvalued or Undervalued? — Valuation Analysis

IN8BIO, INC. (INAB) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.51x, versus the sector average of 2.75x. The price-to-sales ratio is 39.89x, compared to 1.66x for the average Healthcare stock.

At current multiples, IN8BIO, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IN8BIO, INC. Profitability — ROE, Margins, and Quality Score

IN8BIO, INC. (INAB) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -78.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -66.9% versus the sector average of -33.1%.

The operating margin is -11006.4% (sector: -66.1%). Net profit margin stands at -11006.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 88.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INAB Debt, Balance Sheet, and Financial Health

IN8BIO, INC. has a debt-to-equity ratio of 17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.82x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $11M.

INAB has a beta of 9.67, meaning it is more volatile than the broader market — a $10,000 investment in INAB would be expected to move 867.0% more than the S&P 500 on any given day. The stability factor score for IN8BIO, INC. is 6/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

IN8BIO, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, IN8BIO, INC. reported revenue of $353,000 and earnings per share (EPS) of $-4.44. Net income for the quarter was $-22M. Operating income came in at $-22M.

In FY 2025, IN8BIO, INC. reported revenue of $421,000 and earnings per share (EPS) of $-4.44. Net income for the quarter was $-19M. Revenue grew 83.0% year-over-year compared to FY 2024. Operating income came in at $-19M.

In Q3 2025, IN8BIO, INC. reported revenue of $113,000 and earnings per share (EPS) of $-0.85. Net income for the quarter was $-4M. Revenue grew 391.3% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, IN8BIO, INC. reported revenue of $107,000 and earnings per share (EPS) of $-1.24. Net income for the quarter was $-5M. Revenue grew 78.3% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, IN8BIO, INC. has demonstrated a growth trajectory, with revenue expanding from $60,000 to $353,000. Investors analyzing INAB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INAB Dividend Yield and Income Analysis

IN8BIO, INC. (INAB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INAB Momentum and Technical Analysis Profile

IN8BIO, INC. (INAB) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

INAB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IN8BIO, INC. (INAB) ranks #751 out of 838 stocks based on the Blank Capital composite score. This places INAB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INAB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INAB vs S&P 500 (SPY) comparison to assess how IN8BIO, INC. stacks up against the broader market across all factor dimensions.

INAB Next Earnings Date

No upcoming earnings date has been announced for IN8BIO, INC. (INAB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INAB? — Investment Thesis Summary

The quantitative profile for IN8BIO, INC. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. High volatility (stability score 6/100) increases portfolio risk.

In summary, IN8BIO, INC. (INAB) earns a Avoid rating with a composite score of 22.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INAB stock.

Related Resources for INAB Investors

Explore more research and tools: INAB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INAB head-to-head with peers: INAB vs AZN, INAB vs SLGL, INAB vs VMD.